These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 2382997)
1. CA-50 and CA-19.9 as tumour markers: which is preferable? Maréchal F; Berthiot G; Legrand MG; Larbre H; Cattan A; Deltour G Anticancer Res; 1990; 10(4):977-82. PubMed ID: 2382997 [TBL] [Abstract][Full Text] [Related]
2. Small intestinal mucin antigen (SIMA); a novel tumour marker in colorectal cancer? Eskelinen M; Pasanen P; Janatuinen E; Pettersson N; Linnane A; Alhava E Anticancer Res; 1995; 15(5B):2351-6. PubMed ID: 8572651 [TBL] [Abstract][Full Text] [Related]
3. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700. van Dalen A; Kessler AC Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058 [TBL] [Abstract][Full Text] [Related]
4. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study. Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729 [TBL] [Abstract][Full Text] [Related]
5. [CA-125 in non-ovarian benign and malignant pathology: study on 380 patients]. Marechal F; Berthiot G; Kritly T; Legrand MG; Deltour G; Cattan A Bull Cancer; 1989; 76(7):697-706. PubMed ID: 2819261 [TBL] [Abstract][Full Text] [Related]
6. The serum concentrations of TAG-72 antigen measured with CA 72-4 IRMA in patients with ovarian carcinoma. Preliminary data. Gadducci A; Ferdeghini M; Ceccarini T; Prontera C; Facchini V; Bianchi R; Fioretti P J Nucl Med Allied Sci; 1989; 33(1):32-6. PubMed ID: 2746365 [TBL] [Abstract][Full Text] [Related]
7. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919 [TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer. Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718 [TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of serum TAC-41 in various digestive cancers]. Sato S; Yamanaka T; Kimura K Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083 [TBL] [Abstract][Full Text] [Related]
10. Serum levels of CA-50, CA-19.9, CA-125, CA-15.3, enolase and carcino-embryonic antigen in non neoplastic diseases of the lung. Marechal F; Berthiot G; Deltour G Anticancer Res; 1988; 8(4):677-80. PubMed ID: 3178158 [TBL] [Abstract][Full Text] [Related]
11. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study. Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910 [TBL] [Abstract][Full Text] [Related]
12. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer]. Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018 [TBL] [Abstract][Full Text] [Related]
13. A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers. Kokociñska D; Jarzab B; Król R; Ziaja K; Szejbak K; Kuśmierski S J Environ Pathol Toxicol Oncol; 1996; 15(2-4):283-7. PubMed ID: 9216823 [TBL] [Abstract][Full Text] [Related]
14. [Tag 72: a new tumor-associated antigen identified by a monoclonal antibody]. Piantino P; Fusaro A; Daziano E; Polloni R; Mosso R; Cacace G Minerva Med; 1990 Nov; 81(11):765-7. PubMed ID: 2255410 [TBL] [Abstract][Full Text] [Related]
15. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma. Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259 [TBL] [Abstract][Full Text] [Related]
16. Cancer-associated antigen CA 15-3 in the diagnostics of breast tumours. Eskelinen M; Tikanoja S; Valkamo E; Loikkanen M; Collan Y Scand J Clin Lab Invest; 1988 Nov; 48(7):653-8. PubMed ID: 3201097 [TBL] [Abstract][Full Text] [Related]
17. [Comparison of CA 50 and CA 19-9 tumor markers in benign and malignant diseases of the upper gastrointestinal tract]. Heptner G; Domschke S; Schneider MU; Siegfried W; Domschke W Dtsch Med Wochenschr; 1986 Mar; 111(10):374-8. PubMed ID: 2419074 [TBL] [Abstract][Full Text] [Related]
18. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer. Koelbl H; Schieder K; Neunteufel W; Bieglmayer C Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933 [TBL] [Abstract][Full Text] [Related]
19. [Comparative studies on the value of acute phase proteins and CA-125 for monitoring patients with ovarian cancer]. Kölbl H; Tatra G; Schieder K; Bieglmayer C Strahlenther Onkol; 1988 Dec; 164(12):724-8. PubMed ID: 2462754 [TBL] [Abstract][Full Text] [Related]